Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) Director Chandra P. Leo acquired 10,000 shares of Monte Rosa Therapeutics stock in a transaction on Monday, March 24th. The shares were purchased at an average cost of $5.84 per share, with a total value of $58,400.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company's stock, valued at $58,400. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Monte Rosa Therapeutics Stock Performance
Monte Rosa Therapeutics stock traded down $0.16 during midday trading on Friday, reaching $5.10. 587,051 shares of the stock were exchanged, compared to its average volume of 988,683. Monte Rosa Therapeutics, Inc. has a 52 week low of $3.21 and a 52 week high of $12.40. The firm has a market cap of $313.70 million, a PE ratio of -2.79 and a beta of 1.50. The company's fifty day moving average is $6.15 and its 200-day moving average is $6.76.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.60. The business had revenue of $14.00 million for the quarter, compared to the consensus estimate of $43.73 million. On average, sell-side analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on GLUE. Wedbush reiterated an "outperform" rating and set a $17.00 price target (up previously from $15.00) on shares of Monte Rosa Therapeutics in a research note on Thursday, March 20th. Wells Fargo & Company reduced their target price on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a research note on Friday, March 21st. Finally, Lifesci Capital initiated coverage on shares of Monte Rosa Therapeutics in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 price target on the stock.
Read Our Latest Research Report on Monte Rosa Therapeutics
Institutional Investors Weigh In On Monte Rosa Therapeutics
Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Monte Rosa Therapeutics by 9.2% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,701 shares of the company's stock valued at $172,000 after acquiring an additional 2,084 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Monte Rosa Therapeutics by 192.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company's stock worth $38,000 after purchasing an additional 3,584 shares during the period. Bank of New York Mellon Corp lifted its stake in Monte Rosa Therapeutics by 2.2% in the fourth quarter. Bank of New York Mellon Corp now owns 170,312 shares of the company's stock worth $1,182,000 after purchasing an additional 3,619 shares during the last quarter. Wellington Management Group LLP boosted its position in Monte Rosa Therapeutics by 2.2% during the fourth quarter. Wellington Management Group LLP now owns 221,741 shares of the company's stock valued at $1,539,000 after buying an additional 4,740 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Monte Rosa Therapeutics by 38.2% during the third quarter. JPMorgan Chase & Co. now owns 18,543 shares of the company's stock valued at $98,000 after buying an additional 5,125 shares during the last quarter. Hedge funds and other institutional investors own 79.96% of the company's stock.
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
Further Reading
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
